异动分析 CRO概念+创新药+智能医疗+人民币贬值受益+人工智能 来源：新浪证券-红岸工作室 3月4日，康龙化成涨0.07%，成交额5.93亿元，换手率1.55%，总市值496.07亿元。 主力没有控盘，筹码分布非常分散，主力成交额2.34亿，占总成交额的9.82%。 技术面：筹码平均交易成本为31.02元 1、康龙化成(北京)新药技术股份有限公司的主营业务是从药物发现到药物开发的全流程一体化药物研 究、开发及生产服务。公司的主要产品是实验室化学、生物科学服务、CMC(小分子CDMO)服务、海外 临床研究服务、中国临床研究服务、大分子药物发现及开发与生产服务（CDMO）、细胞与基因治疗实 验室服务、基因治疗药物开发与生产服务（CDMO）。 2、研发前期CRM○龙头,为药企提供药物发现、药物开发两阶段的全流程CRMO解决方案专注于小分子 药物研发服务,业务涉及实验室化学、生物科学、药物安全评价、化学和制剂工艺开发及生产和临床研 究服务等多个领域,药物发现领域国内第二 3、2025年1月6日互动易：公司收购上海机颖有助于进一步推动公司在临床服务领域的数字化转型，随 着AI技术的逐步发展和成熟，将可以提高临床服务的 ...

进入创新与行业景气驱动的成长新纪元 2026年CXO及上游行业投资策略 ——CXO行业系列报告（四） 证券分析师：张静含 A0230522080004 余玉君 A0230522080005 2026.03.03 证 券 研 究 报 告 摘要 www.swsresearch.com 证券研究报告 2 ◼ 本篇报告是继上次《寒冬已过，行业需求逐步回暖》之后的第四篇CXO系列报告，此篇报告我们重点解答市场关注的两大问 题：（1）CXO行业回暖需求修复到了什么阶段？（2）细分投资方向如何选择。 ◼ 复盘： CXO 及上游行业外部扰动因素（美国生物安全法案、药品关税、生物医药投融资走弱等）已边际改善，叠加美联储 2024 年 9 月开启降息周期、国内经济复苏与医药产业升级三重核心驱动，行业正式开启新一轮高景气周期。行业业绩与订 单端呈现显著复苏态势，外需型 CXO 自 2024 年下半年起逐步走出困境，2025 年 1-3 季度订单、收入实现同比双增，在美 联储降息预期与多肽、ADC、小核酸等新分子订单拉动下，具备持续提速潜力；内需型 CXO 历经 2023-2024 年集中降价 后，当前订单端实现量增价稳，收入端有望 ...

Q&A 本次专题报告为什么选择在当前时点发布，核心研究框架与结论是什么？ 本次专题在前期市场已广泛关注实验用猴与临床前 CRO 的基础上，重点补足了 对"实验用猴供需关系及其周期性"的系统分析。研究框架围绕三点展开：第 一，重新梳理实验用猴供需缺口的形成机制与未来演化；第二，结合猴价从 "几千元/只"上行至"20 万出头/只"、再回落至"5 万~6 万/只"并于当前 回到"十几万/只"的周期波动，判断 2026 年猴价存在创新高的可能性；第三， 在下游需求复苏与早研需求景气度提升背景下，临床前 CRO 被判断为 2026 年 CRO 板块中最具确定性与弹性的细分方向，覆盖药明康德、康龙化成、美迪西、 昭衍新药、益诺思等公司。 实验猴供需缺口大，持续看好临床前 CRO20260302 摘要 全球实验用猴供需持续紧张，2024 年中国和美国分别存在近万只和 2-3 万只的缺口。中国曾是主要出口国，但疫情后暂停进出口，加剧国内供 需矛盾，猴价经历大幅波动。 国内实验猴种群老龄化严重，2023 年繁殖母猴中 8 岁以上占比高达 80%，直接压制繁育产能。2019-2022 年高猴价导致种猴大量流失， 且食蟹猴繁育周期 ...

3、2023年9月21日互动易回复：公司为欧美生物创新药公司提供阿尔茨海默相关中间体服务。 4、2025年7月9日互动易，公司现有氟化生产能力包括特殊氟化剂氟化（如四氟化硫、氟化氢吡啶、氟 化氢三乙胺）、氟化氢氟化、氟化钾氟化等。 来源：新浪证券-红岸工作室 2月27日，金凯生科跌1.85%，成交额1.40亿元，换手率6.30%，总市值47.24亿元。 异动分析 CRO概念+减肥药+阿尔茨海默概念+氟化工概念+人民币贬值受益 1、公司的主营业务是为全球知名原研药厂的新药研发项目提供小分子药物中间体以及少量原料药的定 制研发生产服务。公司的主要产品是含氟类CDMO业务、非含氟类CDMO业务。 2、2023年8月8日互动易回复：公司上市的募投项目"医药中间体项目"和"年产 190 吨高端医药产品项目 包含司美格鲁肽（Semaglutide）口服制剂小分子吸收增强剂 SNAC 的中间体。 区间今日近3日近5日近10日近20日主力净流入-1575.73万-2528.60万-2748.99万-9459.02万-1.06亿 5、根据2024年年报，公司海外营收占比为61.18%，受益于人民币贬值。 (免责声明：分析内容来 ...

2、百奥赛图(北京)医药科技股份有限公司于2025-12-10上市，公司主营业务为从事提供基因编辑服务、 临床前药理药效评估服务、模式动物销售、抗体开发及创新药开发。 3、百奥赛图(北京)医药科技股份有限公司是一家主要从事药物开发业务及临床前研究的公司。该公司 通过五个分部开展业务。 来源：新浪证券-红岸工作室 2月26日，百奥赛图涨8.15%，成交额2.11亿元，换手率7.92%，总市值346.39亿元。 异动分析 AI智能体+科创次新股+CRO概念+人民币贬值受益+注册制次新股 1、2026年1月13日互动易：我们通过AI的本地化部署，正在建设抗体药物研发AI智能体。随着千鼠万 抗计划与AI系统深度整合的持续推进，我们将为全球药企提供更加高效的研发工具和更为丰富的抗体 分子库，帮助药企伙伴提高临床前PCC分子的研发效率，这也将推动抗体发现业务迈入全新发展阶段。 区间今日近3日近5日近10日近20日主力净流入218.42万-921.89万-975.39万2306.19万7132.04万 公司简介 4、根据2024年年报，公司海外营收占比为67.94%，受益于人民币贬值。 5、百奥赛图(北京)医药科技股份有限 ...

分红方面，药明康德A股上市后累计派现140.60亿元。近三年，累计派现104.06亿元。 机构持仓方面，截止2025年9月30日，药明康德十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股2.49亿股，相比上期减少5260.71万股。华夏上证50ETF（510050）位居第七大流通股东， 持股4778.07万股，相比上期减少121.71万股。华泰柏瑞沪深300ETF（510300）位居第八大流通股东， 持股4268.15万股，相比上期减少188.65万股。中欧医疗健康混合A（003095）、易方达沪深300医药ETF （512010）退出十大流通股东之列。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 资金流向方面，主力资金净流出2.06亿元，特大单买入1.76亿元，占比9.25%，卖出3.35亿元，占比 17.58%；大单买入3.99亿元，占比20.91%，卖出4.46亿元，占比23.38%。 药明 ...

Group 1: Industry Policy Dynamics - Recent active policy developments in the pharmaceutical industry may indirectly impact companies like Boji Pharmaceutical (300404) and other medical research outsourcing firms [1] - The National Health Commission approved a pilot program for internet-based pediatric specialty consultations in Beijing, marking a significant step towards the standardization of internet healthcare and potentially accelerating the online medical service process [1] - The National Medical Products Administration announced support for innovation in the biomanufacturing industry during the 14th Five-Year Plan, with a projected 17% year-on-year increase in the approval of innovative medical devices by 2025 [1] - Jiangsu Province's medical insurance bureau is advancing a policy to separate the budget for innovative drugs, which aims to alleviate budget constraints for hospitals in the first three years of negotiated drug prices [1] Group 2: Company Stock Performance - Boji Pharmaceutical's stock price has been fluctuating, closing at 10.56 yuan on February 13, 2026, down 1.31% for the day, with a trading volume of 70.75 million yuan [2] - Over the past five days (February 9 to 13), the stock experienced a price change of 0.38%, with a high of 10.82 yuan and a low of 10.48 yuan, resulting in a volatility of 3.23% [2] - On February 13, there was a net inflow of 4.217 million yuan from institutional investors, while retail investors showed a net outflow; technical indicators suggest a short-term consolidation phase [2] Group 3: Institutional Insights - Institutional interest in Boji Pharmaceutical is moderate, with recent sentiment being neutral; a report from Xiangcai Securities noted increased activity in the innovative drug supply chain, but the industry still faces pressure from medical insurance controls [3] - Multiple institutions forecast Boji Pharmaceutical's net profit to reach approximately 45 million yuan in 2025, representing a year-on-year growth of 56.38%, with an expected earnings per share of 0.12 yuan; projections for 2026 suggest a net profit of 66 million yuan and potential revenue expansion [3] - The company’s "Semaglutide Injection" project is currently in Phase III clinical trials, but specific timelines for progress remain unclear, necessitating attention to subsequent clinical results and their potential impact on performance [3]

Core Viewpoint - The U.S. stock market is experiencing a rare and widespread panic sell-off, driven by concerns over AI's disruptive potential across various sectors [1][3] Market Behavior - Over 40 S&P 500 stocks exhibited abnormal volatility exceeding three standard deviations, marking the highest level observed by Goldman Sachs trader Ryan Shakey [1] - Defensive sectors such as utilities, consumer staples, REITs, and healthcare are leading the market, while technology, media, and telecommunications are facing significant declines [1] - The Goldman Sachs AI risk exposure basket (GSTMTAIR) saw a sharp drop of 510 basis points in a single day, indicating heightened market sensitivity to AI-related risks [1] Investor Sentiment - Investor sentiment has shifted dramatically, with a notable loss of appetite for bottom-fishing, as hedge funds and long institutions are selling off but at smaller scales, indicating a growing sense of fatigue [4] - The market breadth has deteriorated sharply, with 350 S&P 500 stocks declining, and major tech companies like Apple, Amazon, Microsoft, Meta, and Cisco dragging down the index [5] Sector-Specific Impacts - The logistics sector has become a recent focal point, with CH Robinson experiencing an eight-standard deviation drop, reflecting the spread of AI panic from tech to traditional industries [6] - Financial stocks, previously seen as safe havens, are also under pressure, with regional banks losing their appeal as attractive investments [6] - The healthcare sector has seen a 32% drop in contract research organizations (CROs) this month, following Pfizer's announcement to utilize AI for most clinical trials [6] Reassessment of AI Winners - The technology, media, and telecommunications sectors, excluding storage chips, are facing widespread declines, as previously regarded "winners" are being sold off amid risk-averse sentiment [7] - Investors are confused about the underlying issues in earnings reports, as fundamental analysis appears to be overlooked in the current panic environment [7]

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom development and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main products of the company include fluorinated CDMO services and non-fluorinated CDMO services [2]. - The company has a significant project involving the production of intermediates for Semaglutide oral formulations, which is part of its fundraising projects [2][3]. - As of the 2024 annual report, overseas revenue accounted for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 488 million yuan, representing a year-on-year growth of 25.96%, and a net profit attributable to shareholders of 103 million yuan, with a remarkable year-on-year increase of 163.24% [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Group 3: Market Activity - On February 12, the company's stock price decreased by 0.21%, with a trading volume of 93.35 million yuan and a turnover rate of 4.24%, resulting in a total market capitalization of 4.659 billion yuan [1]. - The stock has seen a net outflow of 4.177 million yuan from major investors today, with a ranking of 31 out of 52 in its industry [5][6].

Group 1 - The company expects to procure chemical raw materials from its affiliate Gansu Haotian Technology Co., Ltd. with a maximum amount of 50 million yuan by 2026 [1] - The company plans to sell products and provide technical services to a new affiliate, Hangzhou Jiaolian Biomedical Technology Co., Ltd., with a maximum amount of 10 million yuan [1] - These transactions are based on daily operational needs and are expected to be executed within the board's approval authority [1] Group 2 - The company continues to expand in cutting-edge fields such as XDC, PROTAC, peptides, and small nucleic acid drugs, aiming to build an integrated service capability from laboratory to commercial production [2] - Long-term trends such as policy support for the pharmaceutical industry and population aging may present opportunities for the company's innovative drug research and development [2] Group 3 - The pharmaceutical and biotechnology industry is significantly influenced by policies, such as adjustments to medical insurance catalogs and the pace of review and approval for innovative drugs, which may indirectly affect the business demand for the company as a medical research outsourcing entity [3]